{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:50Z","timestamp":1792787930237,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"American Cancer Society","id":[{"id":"https:\/\/ror.org\/02e463172","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Grant from Karolinska Institutet","id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low-dose aspirin use is associated with reduced CRC incidence and CRC-related mortality. A similar association with P2Y12 inhibitor use remains uncertain. We investigated whether the use of P2Y12 inhibitors was associated with CRC incidence and CRC-related mortality among individuals diagnosed with atherosclerotic cardiovascular disease (ASCVD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From the ESPRESSO cohort, we identified 334,882 patients diagnosed with ASCVD between 2006 and 2021. We identified patients who initiated P2Y12 inhibitors \u2265 84 consecutive Defined Daily Doses (cDDDs). We estimated the risk of incident CRC and CRC mortality according to P2Y12 inhibitor use using Cox proportional-hazards regression models adjusting for potential confounders including comorbidities and regular aspirin use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We documented 4,015 incident CRC cases and 2,610 CRC-related deaths during a median follow-up of 5.1 years (IRQ, 2.1\u20139.0 years). We did not observe an association between P2Y12 inhibitor use and CRC incidence. In contrast, a longer duration of P2Y12 inhibitor use was associated with lower CRC-related mortality. Compared to non-users, multivariable-adjusted hazard ratio (HR) for CRC mortality were 0.73 (95% CI, 0.60\u20130.89) in patients with 336\u2013671 cDDDs of P2Y12 inhibitor and 0.81 (95% CI, 0.68\u20130.97) in those with \u2265672 cDDDs. Among patients with incident CRC diagnosis, subsequent initiation of P2Y12 inhibitor after CRC diagnosis was associated with significantly lower CRC mortality (HR 0.42; 95% CI, 0.29\u20130.60).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>P2Y12 inhibitor use was not associated with risk of incident CRC but was significantly inversely associated with CRC mortality, which appeared to be due to improved survival among individuals who initiate P2Y12 inhibitors after CRC diagnosis. These findings merit further study given the observational nature of the analysis and potential for residual confounding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-05422-z","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:31:04Z","timestamp":1791826264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Platelet P2Y12 inhibitor use and risk of colorectal cancer incidence and colorectal cancer-related mortality: a Swedish registry-based cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Michael","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bottai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey G.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas F.","family":"Ludvigsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"5422_CR1","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.tranon.2021.101174","volume":"14","author":"Y Xi","year":"2021","unstructured":"Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:101174.","journal-title":"Transl Oncol"},{"key":"5422_CR2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","volume":"13","author":"AM Algra","year":"2012","unstructured":"Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518\u201327.","journal-title":"Lancet Oncol"},{"key":"5422_CR3","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","volume":"376","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741\u201350.","journal-title":"Lancet"},{"key":"5422_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1001\/jamaoncol.2020.7338","volume":"7","author":"C-G Guo","year":"2021","unstructured":"Guo C-G, Ma W, Drew DA, Cao Y, Nguyen LH, Joshi AD, et al. Aspirin use and risk of colorectal cancer among older adults. JAMA Oncol. 2021;7:428\u201335.","journal-title":"JAMA Oncol"},{"key":"5422_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMoa021735","volume":"348","author":"JA Baron","year":"2003","unstructured":"Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891\u20139.","journal-title":"N Engl J Med"},{"key":"5422_CR6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/M16-0577","volume":"164","author":"K Bibbins-Domingo","year":"2016","unstructured":"Bibbins-Domingo K. Aspirin use for the primary prevention of Cardiovascular Disease and Colorectal Cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016;164:836\u201345.","journal-title":"Ann Intern Med"},{"key":"5422_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1146\/annurev-med-060319-120913","volume":"72","author":"DA Drew","year":"2021","unstructured":"Drew DA, Chan AT. Aspirin in the prevention of Colorectal Neoplasia. Annu Rev Med. 2021;72:415\u201330.","journal-title":"Annu Rev Med"},{"key":"5422_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrc.2016.4","volume":"16","author":"DA Drew","year":"2016","unstructured":"Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer. 2016;16:173\u201386.","journal-title":"Nat Rev Cancer"},{"key":"5422_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1124\/mol.113.084988","volume":"84","author":"Dovizio","year":"2013","unstructured":"Dovizio, Maier M, Alberti TJ, Francesco S, Di L, Marcantoni E, et al. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Mol Pharmacol. 2013;84:25\u201340.","journal-title":"Mol Pharmacol"},{"key":"5422_CR10","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","volume":"30","author":"L Wallentin","year":"2009","unstructured":"Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30:1964\u201377.","journal-title":"Eur Heart J"},{"key":"5422_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11239-011-0667-5","volume":"33","author":"P Damman","year":"2012","unstructured":"Damman P, Woudstra P, Kuijt WJ, de Winter RJ, James SK. P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis. 2012;33:143\u201353.","journal-title":"J Thromb Thrombolysis"},{"key":"5422_CR12","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.cgh.2018.12.012","volume":"17","author":"A Rodr\u00edguez-Miguel","year":"2018","unstructured":"Rodr\u00edguez-Miguel A, Garc\u00eda-Rodr\u00edguez LA, Gil M, Montoya H, Rodr\u00edguez-Mart\u00edn S, de Abajo FJ. Clopidogrel and low-dose aspirin, alone or together, reduce risk of colorectal cancer. Clin Gastroenterol Hepatol. 2018;17:2024\u20132033.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5422_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF, Almqvist C, Bonamy A-KE, Ljung R, Micha\u00eblsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31:125\u201336.","journal-title":"Eur J Epidemiol"},{"key":"5422_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CLEP.S191914","volume":"11","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Lashkariani M. Cohort profile: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden). Clin Epidemiol. 2019;11:101\u201314.","journal-title":"Clin Epidemiol"},{"key":"5422_CR15","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, MichaelFored C, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish prescribed drug register\u2014opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5422_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0167-5273(00)00366-1","volume":"76","author":"A Linnersj\u00f6","year":"2000","unstructured":"Linnersj\u00f6 A, Hammar N, Gustavsson A, Reuterwall C. Recent time trends in acute myocardial infarction in Stockholm, Sweden. Int J Cardiol. 2000;76:17\u201321.","journal-title":"Int J Cardiol"},{"key":"5422_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim J-L, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health"},{"key":"5422_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ejvs.2016.12.031","volume":"53","author":"AN Lasota","year":"2017","unstructured":"Lasota AN, Overvad K, Eriksen HH, Tj\u00f8nneland A, Schmidt EB, Gr\u00f8nholdt M-LM. Validity of peripheral arterial disease diagnoses in the danish national patient registry. Eur J Vasc Endovasc Surg. 2017;53:679\u201385.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"5422_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","volume":"24","author":"JF Ludvigsson","year":"2009","unstructured":"Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659\u201367.","journal-title":"Eur J Epidemiol"},{"key":"5422_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, Talb\u00e4ck M, H\u00f6rnblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32:765\u201373.","journal-title":"Eur J Epidemiol"},{"key":"5422_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","volume":"48","author":"L Barlow","year":"2009","unstructured":"Barlow L, Westergren K, Holmberg L, Talb\u00e4ck M. The completeness of the Swedish Cancer Register \u2013 a sample survey for year 1998. Acta Oncologica. 2009;48:27\u201333.","journal-title":"Acta Oncologica"},{"key":"5422_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CLEP.S282475","volume":"13","author":"JF Ludvigsson","year":"2021","unstructured":"Ludvigsson JF, Appelros P, Askling J, Byberg L, Carrero J-J, Ekstr\u00f6m AM, et al. Adaptation of the charlson comorbidity index for register-based research in Sweden. Clin Epidemiol. 2021;13:21\u201341.","journal-title":"Clin Epidemiol"},{"key":"5422_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","volume":"34","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Svedberg P, Ol\u00e9n O, Bruze G, Neovius M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34:423\u201337.","journal-title":"Eur J Epidemiol"},{"key":"5422_CR24","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","volume":"18","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18:800\u20134.","journal-title":"Epidemiology"},{"key":"5422_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2147\/CLEP.S90589","volume":"7","author":"JF Ludvigsson","year":"2015","unstructured":"Ludvigsson JF, H\u00e5berg SE, Knudsen GP, Lafolie P, Zoega H, Sarkkola C, et al. Ethical aspects of registry-based research in the Nordic countries. Clin Epidemiol. 2015;7:491\u2013508.","journal-title":"Clin Epidemiol"},{"key":"5422_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/ije\/dym193","volume":"36","author":"GA Kune","year":"2007","unstructured":"Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations and medications: case\u2013control results from the Melbourne Colorectal Cancer Study\u2020. Int J Epidemiol. 2007;36:951\u20137.","journal-title":"Int J Epidemiol"},{"key":"5422_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","volume":"159","author":"NR Cook","year":"2013","unstructured":"Cook NR, Lee I-M, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77\u201385.","journal-title":"Ann Intern Med"},{"key":"5422_CR28","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","volume":"395","author":"J Burn","year":"2020","unstructured":"Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin J-P, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395:1855\u201363.","journal-title":"Lancet"},{"key":"5422_CR29","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.294.8.914","volume":"294","author":"AT Chan","year":"2005","unstructured":"Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294:914\u201323.","journal-title":"JAMA"},{"key":"5422_CR30","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00432-022-03942-1","volume":"148","author":"JC M\u00e4dge","year":"2022","unstructured":"M\u00e4dge JC, Stallmach A, Kleebusch L, Schlattmann P. Meta-analysis of aspirin-guided therapy of colorectal cancer. J Cancer Res Clin Oncol. 2022;148:1407\u201317.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5422_CR31","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s10654-023-01024-1","volume":"38","author":"L Emilsson","year":"2023","unstructured":"Emilsson L, Song M, Ludvigsson JF. Target trial emulation of aspirin after diagnosis of colorectal polyps. Eur J Epidemiol. 2023;38:1105\u201314.","journal-title":"Eur J Epidemiol"},{"key":"5422_CR32","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","volume":"367","author":"X Liao","year":"2012","unstructured":"Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin Use, Tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367:1596\u2013606.","journal-title":"N Engl J Med"},{"key":"5422_CR33","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-13-2563","volume":"20","author":"D Tougeron","year":"2014","unstructured":"Tougeron D, Sha D, Manthravadi S, Sinicrope FA. Aspirin and colorectal cancer: back to the future. Clin Cancer Res. 2014;20:1087\u201394.","journal-title":"Clin Cancer Res"},{"key":"5422_CR34","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1056\/NEJMoa067208","volume":"356","author":"AT Chan","year":"2007","unstructured":"Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356:2131\u201342.","journal-title":"N Engl J Med"},{"key":"5422_CR35","first-page":"S45","volume":"19","author":"C Patrono","year":"2001","unstructured":"Patrono C. Measurement of cyclooxygenase isozyme inhibition in humans: exploring the clinical relevance of biochemical selectivity. Clin Exp Rheumatol. 2001;19:S45\u201350.","journal-title":"Clin Exp Rheumatol"},{"key":"5422_CR36","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.cgh.2019.02.033","volume":"17","author":"M Jovani","year":"2019","unstructured":"Jovani M, Chan AT. Do aspirin and clopidogrel follow the same road toward prevention of colorectal cancer? Clin Gastroenterology Hepatology. 2019;17:1945\u20137.","journal-title":"Clin Gastroenterology Hepatology"},{"key":"5422_CR37","doi-asserted-by":"publisher","first-page":"e0159179","DOI":"10.1371\/journal.pone.0159179","volume":"11","author":"L Cea Soriano","year":"2016","unstructured":"Cea Soriano L, Soriano-Gabarr\u00f3 M, Garc\u00eda Rodr\u00edguez LA. The protective effect of low-dose aspirin against colorectal cancer is unlikely explained by selection bias: results from three different study designs in clinical practice. PLoS ONE. 2016;11:e0159179.","journal-title":"PLoS ONE"},{"key":"5422_CR38","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.amjmed.2017.01.022","volume":"130","author":"A Leader","year":"2017","unstructured":"Leader A, Zelikson-Saporta R, Pereg D, Spectre G, Rozovski U, Raanani P, et al. The effect of combined aspirin and clopidogrel treatment on cancer incidence. Am J Med. 2017;130:826\u201332.","journal-title":"Am J Med"},{"key":"5422_CR39","doi-asserted-by":"publisher","first-page":"32462","DOI":"10.18632\/oncotarget.8655","volume":"7","author":"P Guillem-Llobat","year":"2016","unstructured":"Guillem-Llobat P, Dovizio M, Bruno A, Ricciotti E, Cufino V, Sacco A, et al. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget. 2016;7:32462\u201377.","journal-title":"Oncotarget"},{"key":"5422_CR40","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2017-05-743187","volume":"131","author":"XR Xu","year":"2018","unstructured":"Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018;131:1777\u201389.","journal-title":"Blood"},{"key":"5422_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jaccao.2020.04.009","volume":"2","author":"JR Wright","year":"2020","unstructured":"Wright JR, Chauhan M, Shah C, Ring A, Thomas AL, Goodall AH, et al. The TICONC (Ticagrelor-Oncology) study: implications of P2Y(12) Inhibition for metastasis and cancer-associated thrombosis. JACC CardioOncol. 2020;2:236\u201350.","journal-title":"JACC CardioOncol"},{"key":"5422_CR42","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","volume":"640","author":"J Yang","year":"2025","unstructured":"Yang J, Yamashita-Kanemaru Y, Morris BI, Contursi A, Trajkovski D, Xu J, et al. Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity. Nature. 2025;640:1052\u201361. https:\/\/doi.org\/10.1038\/s41586-025-08626-7","journal-title":"Nature"},{"key":"5422_CR43","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","volume":"73","author":"N Ferri","year":"2013","unstructured":"Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73:1681\u2013709.","journal-title":"Drugs"},{"key":"5422_CR44","doi-asserted-by":"publisher","first-page":"100794","DOI":"10.1016\/j.eclinm.2021.100794","volume":"34","author":"C Zhang","year":"2021","unstructured":"Zhang C, Cheng Y, Luo D, Wang J, Liu J, Luo Y, et al. Association between cardiovascular risk factors and colorectal cancer: A systematic review and meta-analysis of prospective cohort studies. eClinicalMedicine. 2021;34:100794 https:\/\/doi.org\/10.1016\/j.eclinm.2021.100794","journal-title":"eClinicalMedicine"},{"key":"5422_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10654-023-01073-6","volume":"39","author":"G Chauca Strand","year":"2024","unstructured":"Chauca Strand G, Str\u00f6mberg U, Forsberg A, Bonander C. Impact of organised colorectal cancer screening on age-specific population incidences: evidence from a quasi-experimental study in Sweden. Eur J Epidemiol. 2024;39:87\u201396.","journal-title":"Eur J Epidemiol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05422-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05422-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05422-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:02:29Z","timestamp":1791928949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-05422-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5422"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05422-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This project (2014\/1287-31\/4) was approved by the Research Ethics Committee in Stockholm, Sweden on August 27, 2014; with additional amendments 2018\/972-32 (May 14, 2018) and 2022-05774-02 (November 14, 2022).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Song is a consultant for Eiome Inc.. Dr. Chan served as a consultant for Pfizer Inc., and Boehringer Ingelheim and received grants from Pfizer Inc, Zoe Ltd, and Freenome. Dr. Ludvigsson has coordinated an unrelated study on behalf of the Swedish IBD quality register (SWIBREG). That study received funding from Janssen corporation. Dr. Ludvigsson has also received financial support from MSD developing a paper reviewing national healthcare registers in China. Dr. Ludvigsson has an ongoing research collaboration with Takeda about celiac disease. The other authors do not have conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"641"}}